Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation in the United Kingdom (UK) for YESINTEK.
Landmark Science, a provider of real-world evidence (RWE) solutions, is "redefining industry standards" with its white-glove, high-touch approach to evidence generation.
ProBioGen has announced an agreement with Polpharma Biologics, an international biotech company dedicated to the development and manufacture of biosimilars.
Bionova Scientific has announced it has licensed ATUM’s proprietary Leap-In Transposase transposon-based gene delivery and its miCHO cell line development technologies.
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, is collaborating with Cytiva to provide customers with an integrated offering for optimised biologics production.
Thermo Fisher Scientific is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months.
Ray Baldwin, business development manager, Watson-Marlow Fluid Technology Solutions (WMFTS) explains how all single-use is not created equal and how you can tell the difference.
mAbTree Biologics has signed an exclusive co-development and commercialisation partnership with Shilpa Biologicals Pvt, a fully owned subsidiary of Shilpa Medicare, for its biologic asset for immuno-oncological applications.
Syngene International, a contract research, development, and manufacturing organisation (CRDMO), has announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
In biopharma manufacturing, every second counts. Like in any industry, operational downtime breeds inefficiency. In the context of manufacturing, it can delay critical research and disrupt production and as a result.
